Rituximab biosimilars comparison

Biosimilars

Compare rituximab biosimilars to brand Rituxan. Rituximab is FDA-approved for NHL, CLL, RA and other conditions on its label. Biosimilars offer significant cost savings for this widely used infusion therapy.

Select any two to compare side by side

All products in this comparison

ProductManufacturerRouteFrequencyKey difference
Rituxan (reference)Genentech/RocheIV infusionVaries by indication (2 doses for RA, 4–8 cycles for oncology)Original reference product; decades of clinical experience
Truxima (rituximab-abbs)CelltrionIV infusionSame as referenceFirst FDA-approved rituximab biosimilar
Ruxience (rituximab-pvvr)PfizerIV infusionSame as referencePfizer biosimilar; widely available
Riabni (rituximab-arrx)AmgenIV infusionSame as referenceAmgen biosimilar; competitive pricing

Related guides

Denied one of these medications?

Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.